PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE TATEMENT BY APPLICANT

e as many sheets as necessary)

OF

Complete if Known	
Applicati n Number 09/810,883	
Filing Dat March 16, 2001	
First Named Inventor David THOMAS et al.	
Group Art Unit 1614	
Examiner Name: To Be Assigned	
Attorney Docket Number: TNX 98-08-01	

			U.S. PATENT I	DOCUMENTS	
Examiner Initials	U.S. Documents		U.S. Patent Document Name of	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant
	Number	Kind Code (if known)	Patentee or Applicant of Cited Document	MM-DD-YYYY	Passages or Relevant Figures Appear
W	4,179,337	B1	Davis, et al.	12-18-1979	
	4,495,285	B1	Shimizu, et al.	01-22-1985	
	4,609,546	B1	Hiratani	09-02-1986	
	4,766,106	B1	Katre, et al.	08-23-1988	
	5,225,539	B1	Winter	07-06-1993	
W	5,534,254	B1	Huston, et al.	07-09-1996	
17	5,693,761	B1	Queen, et al.	12-02-1997	
V	5,693,762	B1	Queen, et al.	12-02-1997	

				FOREIGN DOCU	MENTS		
	F	Foreign Patent Documents		Name of Patentee or Applicant of Cited	Date of Publication of	Pages, Columns, Lines, Where	Translation
Examiner Initials	Office	Number Kind Co (if know		Document	Cited Document MM-DD- YYYY	Relevant Passages or Relevant Figures Appear	ranslation
W	wo	98/09638	A1	Katz. et al.	03-12-1998		Abstract
.4	wo	96/40788	A1	Guyre, et al.	12-19-1996		
	EP	0 396 505	A2	Heusser, et al.	11-07-1990		
	EP	0 861 891	A1	Daeron, et al.	09-02-1998		

Examiner Signature		0	Date Considered	9/1163	
	-	Y			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary)

Complete if Known

Application Numb r 09/810,883

Filing Dat March 16, 2001

First Nam d Inv nt r David THOMAS t al.

Group Art Unit 1614

2 OF

4

Examiner Name: To Be Assigned

Attorney Docket Number: TNX 98-08-01

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Examiner Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title Cite T 2 Initials No. of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volumeissue number(s), KARPOVSKY, B., "Production of Target-Specific Effector Cells Using Hetero-Cross-C1 Linked Aggregates Containing Anti-Target Cell and Anti-Fcy Receptor Antibodies, J. Exp. Med. 160:1686-1701 (1984). HOLGATE, S. T., "The role of mast cells and basophils in inflammation", Clin. Exp. C2 Allergy, 30(1):28-32 (2000). KATZ, H.R. et al., "Mouse mast cell gp49B1 contains two immunoreceptor tyrosine-C3 based inhibition motifs and suppresses mast cell activation when colligated with the high affinity Fc receptor for IgE", Proc. Nat. Acad. Sci. USA 93:10809-10814 (1996). EVANS, M.J. et al., "Rapid expression of an anti-human C5 chimeric Fab utilizing a C4 vector that replicates in COS and 293 cells J.Immunol., Vol. 184, pp. 123-138 (1995).RIECHMANN, L. et al., "Reshaping human antibodies for therapy", Nature 332:323-C5 327 (1988). KATZ, H.R. et al., "Activation and Phorbol Ester-Stimulated Phosphorylation of a C6 Plasma Membrane Glycoprotein Antigen Expressed on Mouse IL-3-Dependent Mast Cells and Serosal Mast Cells", J.Immunol., Vol. 142(3): 919-926 (1989). LOW, N.M. et al., "Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain", J. Mol. C7 Biol. 260:359-368 (1996). ISAKOV, N., "ITIMs and ITAMs", Immunol. Res., 16:85-100 (1997). C8 HUBER, M. et al., "The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation", Proc. Nat. Acad. Sci. USA 95:11330-11335 C9 (1998).KIRSHENBAUM, A.S. et al., "Effect of IL-3 and Stem Cell Factor on the Appearance of Human Basophils and Mast Cells from CD34+ Pluripotent Progenitor Cells", J. C10 Immunol. 148(3):772-777 (1992). GREENMAN, J. et al., "Characterization of a New Monoclonal Anti- Fcy RII Antibody, C11 AT10, and its Incorporation into a Bispecific F(ab'), Derivative for Recruitment of Cytotoxic Effectors", Mol. Immunol. 28(11):1243-1254 (1991). LARDOT, C. et al., "Expression of plasminogen activator inhibitors type-1 and type-2" C12 in the mouse lung after administration of crystalline silica", Eur. Respir. J. 11:912-921 (1998).Date Examiner Considered Signature

*EXAMINER: Initial if reference considered, whether or not citation is in comormance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Applicati n Number 09/810,883

Filing Dat March 16, 2001

First Named Inv nt r David THOMAS t al.

Group Art Unit 1614

Examiner Name: To Be Assigned

Attorney Docket Number: TNX 98-08-01

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	Т2				
W	C13	LEUNG, D.Y.M., "Molecular Basis of Allergic Diseases", <i>Mol. Genet. And Metab.</i> 63:157-167 (1998).					
	C14	MALBEC, O. et al., "Fcε Receptor I-Associated <i>lyn</i> -Dependent Phosphorylation of Fcγ Receptor IIB During Negative Regulation of Mast Cell Activation", <i>J. Immunol</i> . 160:1647-1658 (1998).					
	C15	OCHI, H. et al., "T Helper Cell Type 2 Cytokine-mediated Comitogenic Responses and CCR3 Expression During Differentiation of Human Mast Cells In Vitro", <i>J. Exp. Med.</i> 190(2):267-280 (1999).					
	C16	ROCHE, W. et al., "Subepithelial Fibrosis in the Bronchi of Asthmatics", Lancet March 11, 1989, pp. 520-524 (1989).					
	C17	RENARD, V. et al., "Transduction of cytotoxic signals in natural killer cells: a general model of fine tuning between activatory and inhibitory pathways in lymphocytes", <i>Immunol. Rev.</i> 155:205-221 (1997).					
	C18	SAINTE-LAUDY, J. et al., "Analysis of anti-IgE and allegrgen induced human basophil activation by cytometry. Comparison with Histamine release", <i>Inflam. Res.</i> 47:401-408 (1998).					
T	C19	SILIBAR, C. et al. "Type β Transforming Growth Factors Promote Interleukin-3 (IL-3)-Dependent Differentiation of Human Basophils But Inhibit IL-3-Dependent Differentiation of Human Eosinophils", <i>Blood</i> 80(3):634-641 (1992).					
	C20	BLÉRY, M et al., "Reconstituted Killer Cell Inhibitory Receptors for Major Histocompatibility Complex Class I Molecules Control Mast Cell Activation Induced via Immunoreceptor Tyrosine-based Activation Motifs", <i>J. Biol. Chem.</i> 272(14):8989-8996 (1997).					
	C21	DAËRON, M. et al., "Regulation of High-affinity IgE Receptor-mediated Mast Cell Activation by Murine Low affinity IgG Receptors", <i>J. Clin. Invest.</i> 95:577-585 (1995).					
	C22	VIVIER, E. et al., "Immunoreceptor tyrosine-based inhibition motifs", <i>Immunol. Today</i> 18(6):286-291 (1997).					
/	C23	DAËRON, M., "Building up the family of ITIM-bearing negative coreceptors", Immunol. Letters 54:73-76 (1996).					
V	C24	GLENNIE, M.J. et al., "Preparation and Performance of Bispecific F(ab'γ) ₂ Antibody Containing Thioether-Linked Fab' Fragments", <i>J. Immunol.</i> 139(7):2367-2375 (1987).					

*EXAMINER: Initial if reference considered, whether or not citation is in comormance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IPE INFORMATION DISCLOSURE	Complete if Known
STATEMENT BY APPLICANT	Applicati n Number 09/810,883
	Filing Date March 16, 2001
JUN 1 5 700 (E) e as many sheets as necessary)	First Named Inventor David THOMAS et al.
SHEET 4 OF 4	Group Art Unit 1614
SHEET 4 OF 4	Examiner Name: To Be Assigned
	Attorney Docket Number: TNX 98-08-01

	1	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	T
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	Τ2
10	C25	GRASHOFF, W.F.H. et al., "Chronic Obstructive Pulmonary Disease: Role of Bronchiolar Mast Cells and Macrophages", <i>Am. J. Pathol.</i> 151(6):1785-1790 (1997).	
	C26	DAËRON, M. et al., "Biology of Immunoreceptor Tyrosine-Based Inhibition Motif-Bearing Molecules", <i>In:</i> <u>Immunoreceptor Tyrosine Based Inhibition Motifs</u> , DAËRON ed., Chapter 1, Springer (1999).	
V	C27	DiBATTISTA, J.A. et al., "Coordination Regulation of Matrix Metalloproteases and Tissue Inhibitor of Metalloproteinase Expression in Human Synovial Fibroblasts", <i>J. Rheumatol.</i> 22(Suppl 43):123128 (1995).	
V	C28	FLEMING, T.J. et al., "Negative Regulation of FcɛRl-mediated Degranualtion by CD81", J. Exp. Med. 186(8):1307-1314 (1997).	
 .			
			-
Examiner		Date Sula	1

*EXAMINER: Initial if reference considered, whether or not citation is in comormance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUN 1 5 2001 SEE TRADEMENT

The state of the s